Drug Profile


Alternative Names: Anti-VEGF monoclonal antibody; Avastin; RG-435; rhuMAb-VEGF; RO-4876646

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Genentech; Hackensack University Medical Center
  • Developer All Ireland Cooperative Oncology Research Group; Austrian Breast & Colorectal Cancer Study Group; Beth Israel Deaconess Medical Center; Breast Cancer Research Foundation; Brigham and Women's Hospital; Bristol-Myers Squibb; Cancer and Leukemia Group B; Cancer Research UK; Chugai Pharmaceutical; Dana-Farber Cancer Institute; Duke University; European Organisation for Research and Treatment of Cancer; European Thoracic Oncology Platform; Genentech; Hackensack University Medical Center; Japan Breast Cancer Research Group; Massachusetts General Hospital; Medical University of South Carolina; Melanoma Research Foundation Breakthrough Consortium; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); National Comprehensive Cancer Network; NCIC Clinical Trials Group; North Central Cancer Treatment Group; NSABP Foundation; Peter MacCallum Cancer Centre; Roche; Royal Marsden NHS Foundation Trust; Sanofi; Sarcoma Alliance for Research through Collaboration; SCRI Development Innovations; South Eastern European Research Oncology Group; Spanish Cooperative Group for Digestive Tumour Therapy; Spanish Lung Cancer Group; Stanford University School of Medicine; SWOG; The Catalan Institute of Oncology; University College London; University of Alabama at Birmingham; University of Arkansas System; University of California, Davis; University of Tennessee; University of Texas M. D. Anderson Cancer Center; US Oncology Research; West German Study Group; Xijing Hospital
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Mesothelioma; Cervical cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Cervical cancer; Colorectal cancer; Glioblastoma; Glioma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma
  • Phase III Head and neck cancer
  • Phase II Brain metastases; Fallopian tube cancer; Gynaecological cancer; Hepatocellular carcinoma; Hodgkin's disease; Liver cancer; Liver metastases; Malignant melanoma; Multiple myeloma; Neuroblastoma; Neurofibromatoses; Peritoneal cancer; Rectal cancer; Soft tissue sarcoma
  • Phase I/II Neoplastic meningitis
  • Suspended Carcinoid tumour
  • Discontinued Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Eye disorders; Gastric cancer; Gastrointestinal stromal tumours; Mesothelioma; Oesophageal cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer

Most Recent Events

  • 01 May 2017 Catharina Ziekenhuis Eindhoven, Roche, Comprehensive Cancer Centre and Dutch Cancer Society initiate enrolment in the phase II/III CAIRO6 trial for Colorectal cancer (Neoadjuvant therapy, Combination therapy) in Netherlands (NCT02758951)
  • 25 Apr 2017 Discontinued - Phase-III for Mesothelioma (Combination therapy, Inoperable/Unresectable, First-line therapy) in Japan (IV) (Chugai pipeline, April 2017)
  • 21 Apr 2017 Committee for Medicinal Products for Human Use (CHMP) of the EMA recommends approval of extension of indication in ovarian cancer, Fallopian tube cancer and Peritoneal cancer in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top